Personalis, Inc. to Present at Biomarkers Week On-line 2021

MENLO PARK, Calif.–(Small business WIRE)–Personalis, Inc. (Nasdaq: PSNL), a chief in highly developed genomics for cancer, currently announced that the business will existing at Biomarkers Week On the net 2021.

The presentation, titled “ImmunoID Next Platform® for comprehensive tumor immunogenomics and state-of-the-art biomarker discovery,” will describe the Personalis universal most cancers immunogenomics system, ImmunoID Up coming™. Erin Newburn, MS, PhD, will present for Personalis. Dr. Newburn will present an overview of the system, which brings together really sensitive, exome-scale DNA and RNA sequencing with advanced analytics to give a multidimensional view of the tumor and the tumor microenvironment (TME) from a one sample planning. Dr. Newburn will evaluation a scenario examine in a cohort of 51 late-phase melanoma individuals that demonstrates how the integration of neoantigen load, HLA LOH, and Antigen Presentation Equipment (APM) mutational knowledge fashioned a composite biomarker that extra accurately predicted reaction to checkpoint blockade than other markers. Additionally, Dr. Newburn will spotlight our Subsequent Liquid Biopsy™, an exome-huge liquid biopsy tactic merged with ImmunoID Following, to further more take a look at critical locations of tumor biology.

ImmunoID Following is the 1st platform to allow in depth assessment of each a tumor and its immune microenvironment from a one sample. The ImmunoID Up coming System can be utilised to look into the important tumor- and immune-related regions of most cancers biology, consolidating several oncology biomarker assays into a person and maximizing the biological information that can be created from a precious tumor specimen.

Personalis is a co-sponsor of Biomarkers 7 days and will have representatives offered to reply concerns about the company’s cancer immunogenomics capabilities.

About Personalis, Inc.

Personalis, Inc. is a leader in population sequencing and most cancers genomics, with a aim on knowledge, scale, effectiveness, and high quality. Personalis operates one of the largest sequencing functions globally and is at present the sole sequencing service provider to the VA MVP. In oncology, Personalis is reworking the improvement of up coming-generation therapies by supplying more in depth molecular details about every patient’s cancer and immune response. The Personalis® ImmunoID Upcoming Platform is created to adapt to the complex and evolving comprehension of cancer, giving its biopharmaceutical clients with facts on all of the approximately 20,000 human genes, alongside one another with the immune process, from a one tissue and matched blood sample. The Personalis Medical Laboratory is GxP aligned as nicely as CLIA’88-certified and CAP-accredited. For extra information, be sure to visit www.personalis.com and stick to Personalis on Twitter (@PersonalisInc).

Forward-Searching Statements

All statements in this press release that are not historical are “forward-searching statements” in just the meaning of U.S. securities rules, including statements relating to attributes or positive aspects of the Personalis Future System, Personalis’ company opportunities, management, programs, eyesight or expansion, or other potential occasions. Such ahead-searching statements contain threats and uncertainties, together with those people related to the COVID-19 pandemic, that could induce genuine outcomes to differ materially from any expected effects or expectations expressed or implied by these statements. Components that could materially impact precise success can be identified in Personalis’ filings with the U.S. Securities and Exchange Fee, such as Personalis’ most modern reviews on Varieties 8-K, 10-K and 10-Q, and incorporate all those outlined under the caption “Risk Components.” Personalis disclaims any obligation to update these types of ahead-wanting statements.